Tian Ruixiang Stock Soars 9.29% on Ucare Acquisition

Tian Ruixiang's stock price surged by 9.29% today, marking its fourth consecutive day of gains, with a cumulative increase of 47.06% over the past four days. The share price reached its highest level since December 2024, with an intraday gain of 17.49%.

The strategy of buying TIRX shares after they reach a high and holding for one week resulted in a 219.37% return, significantly outperforming the benchmark with a 169.92% excess return. However, the strategy had a high maximum drawdown of -54.86% and a Sharpe ratio of 0.33, indicating moderate risk and returns.

The most significant factor driving the recent surge in TIRX's stock price is the strategic acquisition of Ucare Inc. by TIAN RUIXIANG Holdings Ltd. This all-stock deal, valued at US$150 million, was announced on May 30, 2025. The acquisition represents a pivotal shift for TIRX, transitioning from traditional insurance brokerage to a data-driven health insurance innovator. By leveraging Ucare's AI-driven platform and extensive hospital network, TIRX aims to enhance its health insurance offerings and create a unified healthcare ecosystem. This strategic move has bolstered investor confidence, contributing to the stock's recent performance surge.